{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:04:16Z","timestamp":1789009456913,"version":"build-2803163510"},"reference-count":61,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,4,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Here we evaluated whether sequential high-dose chemotherapy (sHD) increased the early complete remission (CR) rate in acute myelogenous leukemia (AML) compared with standard-intensity idarubicin-cytarabine-etoposide (ICE) chemotherapy. This study enrolled 574 patients (age, 16-73 years; median, 52 years) who were randomly assigned to ICE (n = 286 evaluable) or sHD (2 weekly 3-day blocks with cytarabine 2 g\/m2 twice a day for 2 days plus idarubicin; n = 286 evaluable). Responsive patients were risk-stratified for a second randomization. Standard-risk patients received autograft or repetitive blood stem cell-supported high-dose courses. High-risk patients (and standard-risk patients not mobilizing stem cells) underwent allotransplantation. CR rates after 2 induction courses were comparable between ICE (80.8%) and sHD (83.6%; P = .38). sHD yielded a higher single-induction CR rate (69.2% vs 81.5%; P = .0007) with lower resistance risk (P &amp;lt; .0001), comparable mortality (P = .39), and improved 5-year overall survival (39% vs 49%; P = .045) and relapse-free survival (36% vs 48%; P = .028), despite greater hematotoxicity delaying or reducing consolidation blocks. sHD improved the early CR rate in high-risk AML (odds ratio, 0.48; 95% confidence interval [CI], 0.31-0.74; P = .0008) and in patients aged 60 years and less with de novo AML (odds ratio, 0.46; 95% CI, 0.27-0.78; P = .003), and also improved overall\/relapse-free survival in the latter group (hazard ratio, 0.70; 95% CI, 0.52-0.94; P = .01), in standard-risk AML, and postallograft (hazard ratio, 0.61; 95% CI, 0.39-0.96; P = .03). sHD was feasible, effectively achieved rapid CR, and improved outcomes in AML subsets. This study is registered at www.clinicaltrials.gov as #NCT00495287.<\/jats:p>","DOI":"10.1182\/bloodadvances.2018026625","type":"journal-article","created":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T16:54:33Z","timestamp":1554396873000},"page":"1103-1117","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":32,"title":["Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML"],"prefix":"10.1182","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8214-2894","authenticated-orcid":false,"given":"Renato","family":"Bassan","sequence":"first","affiliation":[{"name":"Ospedale dell\u2019Angelo and SS. Giovanni e Paolo, Venezia-Mestre, Italy;"},{"name":"Azienda Socio-Sanitaria Territoriale (ASST) Ospedale Papa Giovanni XXIII, Bergamo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Intermesoli","sequence":"additional","affiliation":[{"name":"Azienda Socio-Sanitaria Territoriale (ASST) Ospedale Papa Giovanni XXIII, Bergamo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Masciulli","sequence":"additional","affiliation":[{"name":"Azienda Socio-Sanitaria Territoriale (ASST) Ospedale Papa Giovanni XXIII, Bergamo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Pavoni","sequence":"additional","affiliation":[{"name":"Azienda Socio-Sanitaria Territoriale (ASST) Ospedale Papa Giovanni XXIII, Bergamo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6905-7038","authenticated-orcid":false,"given":"Cristina","family":"Boschini","sequence":"additional","affiliation":[{"name":"Azienda Socio-Sanitaria Territoriale (ASST) Ospedale Papa Giovanni XXIII, Bergamo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Gianfaldoni","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliera Universitaria Careggi, Firenze, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Marmont","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliero-Universitaria Citt\u00e0 della Salute e della Scienza di Torino, Turin, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Cavattoni","sequence":"additional","affiliation":[{"name":"Ospedale S. Maurizio, Bolzano, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Mattei","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliera S. Croce e Carle di Cuneo, Cuneo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Terruzzi","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliera San Gerardo, Monza, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorella","family":"De Paoli","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cattaneo","sequence":"additional","affiliation":[{"name":"ASST-Spedali Civili, Brescia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Borlenghi","sequence":"additional","affiliation":[{"name":"ASST-Spedali Civili, Brescia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[{"name":"Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Bernardi","sequence":"additional","affiliation":[{"name":"Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Scattolin","sequence":"additional","affiliation":[{"name":"Ospedale dell\u2019Angelo and SS. Giovanni e Paolo, Venezia-Mestre, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Todisco","sequence":"additional","affiliation":[{"name":"IRCCS Istituto Clinico Humanitas di Rozzano, Rozzano, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Campiotti","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Insubria, Varese, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Corradini","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy;"},{"name":"Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostino","family":"Cortelezzi","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Ferrero","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliero-Universitaria Citt\u00e0 della Salute e della Scienza di Torino, Turin, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Zangh\u00ec","sequence":"additional","affiliation":[{"name":"Azienda Socio-Sanitaria Territoriale (ASST) Ospedale Papa Giovanni XXIII, Bergamo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Oldani","sequence":"additional","affiliation":[{"name":"Azienda Socio-Sanitaria Territoriale (ASST) Ospedale Papa Giovanni XXIII, Bergamo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orietta","family":"Spinelli","sequence":"additional","affiliation":[{"name":"Azienda Socio-Sanitaria Territoriale (ASST) Ospedale Papa Giovanni XXIII, Bergamo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesta","family":"Audisio","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliero-Universitaria Citt\u00e0 della Salute e della Scienza di Torino, Turin, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Cortelazzo","sequence":"additional","affiliation":[{"name":"Ospedale S. Maurizio, Bolzano, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bosi","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliera Universitaria Careggi, Firenze, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brunangelo","family":"Falini","sequence":"additional","affiliation":[{"name":"Section of Hematology and Clinical Immunology, Department of Medicine, University of Perugia, Perugia, Italy; and"},{"name":"Centro Ricerche Onco-Ematologiche, Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico M.","family":"Pogliani","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliera San Gerardo, Monza, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3739-7502","authenticated-orcid":false,"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[{"name":"Azienda Socio-Sanitaria Territoriale (ASST) Ospedale Papa Giovanni XXIII, Bergamo, Italy;"},{"name":"Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,4,4]]},"reference":[{"issue":"4","key":"2020021108270603300_B1","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"24","key":"2020021108270603300_B2","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"issue":"1","key":"2020021108270603300_B3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2015-08-604520","article-title":"An update of current treatments for adult acute myeloid leukemia","volume":"127","author":"Dombret","year":"2016","journal-title":"Blood"},{"issue":"8","key":"2020021108270603300_B4","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/ajh.24439","article-title":"Acute myeloid leukemia: 2016 Update on risk-stratification and management","volume":"91","author":"Estey","year":"2016","journal-title":"Am J Hematol"},{"issue":"1","key":"2020021108270603300_B5","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/ajh.24246","article-title":"Acute myeloid leukemia--major progress over four decades and glimpses into the future","volume":"91","author":"Kantarjian","year":"2016","journal-title":"Am J Hematol"},{"issue":"12","key":"2020021108270603300_B6","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N Engl J Med"},{"issue":"25","key":"2020021108270603300_B7","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1182\/blood-2015-01-623447","article-title":"A randomized comparison of daunorubicin 90 mg\/m2 vs 60 mg\/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients","volume":"125","author":"Burnett","year":"2015","journal-title":"Blood"},{"issue":"13","key":"2020021108270603300_B8","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","article-title":"Anthracycline dose intensification in acute myeloid leukemia","volume":"361","author":"Fernandez","year":"2009","journal-title":"N Engl J Med"},{"issue":"24","key":"2020021108270603300_B9","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1200\/JCO.2017.72.8618","article-title":"Prospective randomized comparison of idarubicin and high-dose daunorubicin in induction chemotherapy for newly diagnosed acute myeloid leukemia","volume":"35","author":"Lee","year":"2017","journal-title":"J Clin Oncol"},{"issue":"32","key":"2020021108270603300_B10","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1200\/JCO.2008.20.6490","article-title":"Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10","volume":"27","author":"Mandelli","year":"2009","journal-title":"J Clin Oncol"},{"issue":"8","key":"2020021108270603300_B11","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1182\/blood-2010-03-273243","article-title":"Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study","volume":"117","author":"Ohtake","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2020021108270603300_B12","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1200\/JCO.2009.23.2652","article-title":"Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study","volume":"28","author":"Pautas","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020021108270603300_B13","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1182\/blood.V87.5.1710.1710","article-title":"A randomized study of high-dose cytarabine in induction in acute myeloid leukemia","volume":"87","author":"Bishop","year":"1996","journal-title":"Blood"},{"issue":"1","key":"2020021108270603300_B14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1200\/JCO.2007.15.4245","article-title":"Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group","volume":"27","author":"B\u00fcchner","year":"2009","journal-title":"J Clin Oncol"},{"issue":"11","key":"2020021108270603300_B15","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMoa1010222","article-title":"Cytarabine dose for acute myeloid leukemia","volume":"364","author":"L\u00f6wenberg","year":"2011","journal-title":"N Engl J Med"},{"issue":"8","key":"2020021108270603300_B16","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1182\/blood.V88.8.2841.bloodjournal8882841","article-title":"A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study","volume":"88","author":"Weick","year":"1996","journal-title":"Blood"},{"issue":"3","key":"2020021108270603300_B17","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1200\/JCO.2013.51.8571","article-title":"High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial","volume":"32","author":"Willemze","year":"2014","journal-title":"J Clin Oncol"},{"issue":"10","key":"2020021108270603300_B18","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1200\/JCO.2011.40.5977","article-title":"Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission","volume":"31","author":"Burnett","year":"2013","journal-title":"J Clin Oncol"},{"issue":"20","key":"2020021108270603300_B19","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1200\/JCO.2011.37.1286","article-title":"Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study","volume":"30","author":"Holowiecki","year":"2012","journal-title":"J Clin Oncol"},{"issue":"12","key":"2020021108270603300_B20","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1182\/blood-2016-10-740613","article-title":"Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML","volume":"129","author":"L\u00f6wenberg","year":"2017","journal-title":"Blood"},{"issue":"14","key":"2020021108270603300_B21","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJM199410063311402","article-title":"Intensive postremission chemotherapy in adults with acute myeloid leukemia","volume":"331","author":"Mayer","year":"1994","journal-title":"N Engl J Med"},{"issue":"5","key":"2020021108270603300_B22","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/leu.2013.297","article-title":"Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG","volume":"28","author":"Fiegl","year":"2014","journal-title":"Leukemia"},{"issue":"sup1","key":"2020021108270603300_B23","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3109\/10428199309149125","article-title":"High-dose versus intermediate dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age adjusted randomized comparison","volume":"10","author":"Hiddemann","year":"1993","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2020021108270603300_B24","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/sj.leu.2401066","article-title":"Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison","volume":"12","author":"Kern","year":"1998","journal-title":"Leukemia"},{"issue":"1","key":"2020021108270603300_B25","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/(SICI)1097-0142(19970101)79:1<59::AID-CNCR9>3.0.CO;2-H","article-title":"High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study","volume":"79","author":"Kern","year":"1997","journal-title":"Cancer"},{"issue":"17","key":"2020021108270603300_B26","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1182\/blood-2008-07-162842","article-title":"Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG","volume":"113","author":"Braess","year":"2009","journal-title":"Blood"},{"issue":"29","key":"2020021108270603300_B27","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1200\/JCO.2012.42.2907","article-title":"Acute myeloid leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup","volume":"30","author":"B\u00fcchner","year":"2012","journal-title":"J Clin Oncol"},{"issue":"S2","key":"2020021108270603300_B28","first-page":"272","article-title":"In adult acute myeloid leukaemia (AML) all risk subsets benefit from a sequential high-dose programme as early rescue of first induction failure: a report from Northern Italy Leukaemia Group (NILG)","volume":"95","author":"Intermesoli","year":"2010","journal-title":"Haematologica"},{"issue":"S2","key":"2020021108270603300_B29","first-page":"26","article-title":"Two-step response-oriented induction predicts long-term outcome of adult patients with standard- and high-risk acute myeloid leukaemia (AML): a Northern Italy Leukaemia Group (NILG) study","volume":"95","author":"Intermesoli","year":"2010","journal-title":"Haematologica"},{"issue":"6","key":"2020021108270603300_B30","first-page":"964","article-title":"Factors predicting complete remission and subsequent disease-free survival after a second course of induction therapy in patients with acute myelogenous leukemia resistant to the first","volume":"10","author":"Anderlini","year":"1996","journal-title":"Leukemia"},{"issue":"11","key":"2020021108270603300_B31","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3324\/haematol.2016.148825","article-title":"An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation","volume":"101","author":"Ferguson","year":"2016","journal-title":"Haematologica"},{"issue":"9","key":"2020021108270603300_B32","first-page":"1443","article-title":"Outcome of patients with acute myeloid leukemia who failed to respond to a single course of first-line induction therapy: a GIMEMA study of 218 unselected consecutive patients. Gruppo Italiano Malattie Ematologiche Maligne dell\u2019Adulto","volume":"10","author":"Liso","year":"1996","journal-title":"Leukemia"},{"issue":"26","key":"2020021108270603300_B33","doi-asserted-by":"crossref","first-page":"5818","DOI":"10.1182\/blood-2010-07-296392","article-title":"Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy","volume":"116","author":"Ravandi","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2020021108270603300_B34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1046\/j.1365-2141.1999.01684.x","article-title":"A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council\u2019s Adult and Childhood Leukaemia Working Parties","volume":"107","author":"Wheatley","year":"1999","journal-title":"Br J Haematol"},{"issue":"21","key":"2020021108270603300_B35","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.1002\/cncr.25263","article-title":"Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group","volume":"116","author":"Rowe","year":"2010","journal-title":"Cancer"},{"issue":"6","key":"2020021108270603300_B36","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood.V98.6.1752","article-title":"The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials","volume":"98","author":"Kottaridis","year":"2001","journal-title":"Blood"},{"issue":"3","key":"2020021108270603300_B37","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMoa041974","article-title":"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype","volume":"352","author":"Falini","year":"2005","journal-title":"N Engl J Med"},{"issue":"3","key":"2020021108270603300_B38","first-page":"257","article-title":"Phase I trial with escalating doses of idarubicin and multidrug resistance reversal by short-course cyclosporin A, sequential high-dose cytosine arabinoside, and granulocyte colony-stimulating factor for adult patients with refractory acute leukemia","volume":"87","author":"Bassan","year":"2002","journal-title":"Haematologica"},{"issue":"12","key":"2020021108270603300_B39","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.1182\/blood.V90.12.4710","article-title":"A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia","volume":"90","author":"Heil","year":"1997","journal-title":"Blood"},{"issue":"3","key":"2020021108270603300_B40","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s002770050425","article-title":"Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy for refractory and relapsed acute myeloid leukemia","volume":"77","author":"Kern","year":"1998","journal-title":"Ann Hematol"},{"issue":"13","key":"2020021108270603300_B41","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1182\/blood-2002-03-0772","article-title":"Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)","volume":"100","author":"Byrd","year":"2002","journal-title":"Blood"},{"issue":"7","key":"2020021108270603300_B42","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1182\/blood.V92.7.2322","article-title":"The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial","volume":"92","author":"Grimwade","year":"1998","journal-title":"Blood"},{"issue":"13","key":"2020021108270603300_B43","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1182\/blood.V96.13.4075","article-title":"Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group\/Eastern Cooperative Oncology Group Study","volume":"96","author":"Slovak","year":"2000","journal-title":"Blood"},{"issue":"3","key":"2020021108270603300_B44","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"D\u00f6hner","year":"2010","journal-title":"Blood"},{"issue":"8","key":"2020021108270603300_B45","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1023\/A:1008333903220","article-title":"High-dose treatment with autologous bone marrow support as consolidation of first remission in younger patients with acute myelogenous leukaemia","volume":"11","author":"Rohatiner","year":"2000","journal-title":"Ann Oncol"},{"issue":"5","key":"2020021108270603300_B46","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/bjh.13055","article-title":"Myeloblative therapy with autologous haematopoietic stem cell support as consolidation of first remission in acute myeloid leukaemia - very long follow-up","volume":"167","author":"Rohatiner","year":"2014","journal-title":"Br J Haematol"},{"issue":"4","key":"2020021108270603300_B47","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/sj.thj.6200180","article-title":"Prolonged administration of all-trans retinoic acid in combination with intensive chemotherapy and G-CSF for adult acute myelogenous leukemia: single-centre pilot study in different risk groups","volume":"3","author":"Bassan","year":"2002","journal-title":"Hematol J"},{"issue":"12","key":"2020021108270603300_B48","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1038\/s41375-018-0268-9","article-title":"Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study","volume":"32","author":"Braess","year":"2018","journal-title":"Leukemia"},{"issue":"27","key":"2020021108270603300_B49","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2012.47.4874","article-title":"Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial","volume":"31","author":"Burnett","year":"2013","journal-title":"J Clin Oncol"},{"issue":"13","key":"2020021108270603300_B50","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1182\/blood.V98.13.3575","article-title":"Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts","volume":"98","author":"Estey","year":"2001","journal-title":"Blood"},{"issue":"4","key":"2020021108270603300_B51","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1200\/JCO.2015.63.3826","article-title":"Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission?","volume":"34","author":"Araki","year":"2016","journal-title":"J Clin Oncol"},{"issue":"12","key":"2020021108270603300_B52","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"issue":"11","key":"2020021108270603300_B53","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1200\/JCO.2014.58.3518","article-title":"Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia","volume":"33","author":"Chen","year":"2015","journal-title":"J Clin Oncol"},{"key":"2020021108270603300_B54","author":"Gianfaldoni"},{"issue":"1","key":"2020021108270603300_B55","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1200\/JCO.1995.13.1.148","article-title":"Multicyclic, dose-intensive chemotherapy supported by sequential reinfusion of hematopoietic progenitors in whole blood","volume":"13","author":"Pettengell","year":"1995","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020021108270603300_B56","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1200\/JCO.1997.15.5.1722","article-title":"Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin\u2019s lymphoma","volume":"15","author":"Stoppa","year":"1997","journal-title":"J Clin Oncol"},{"issue":"9","key":"2020021108270603300_B57","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2004-08-2977","article-title":"Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222","volume":"105","author":"Moore","year":"2005","journal-title":"Blood"},{"issue":"9","key":"2020021108270603300_B58","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1200\/JCO.2012.44.3184","article-title":"Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study","volume":"31","author":"Li","year":"2013","journal-title":"J Clin Oncol"},{"issue":"12","key":"2020021108270603300_B59","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"2020021108270603300_B60","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"2020021108270603300_B61","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/7\/1103\/1631451\/advances026625.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/7\/1103\/1631451\/advances026625.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T08:45:14Z","timestamp":1581410714000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/7\/1103\/247274\/Randomized-trial-comparing-standard-vs-sequential"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,4]]},"references-count":61,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,4,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2018026625","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,4]]}}}